PRESS RELEASE: SABCS23: REVEAL GENOMICS® unleashes groundbreaking DNADX® liquid biopsy data for metastatic breast cancer

INFORMATION FOR HEALTHCARE PROFESSIONALS

Packaging of the product DNADX

DNADX® analyzes tumor tissue or plasma circulating tumor DNA to identify clinically relevant biomarkers. The test provides Copy Number Alteration (CNA)-based molecular subtyping* and reports Single Nucleotide Variants (SNVs), indels, and CNAs in breast cancer driver genes.

*Based on REVEAL GENOMICS’ proprietary machine-learning model,
Xia, Y., et al. Nat. Commun. (2019). doi: 10.1038/s41467-019-13588-2
Prat,A., et al.. Nat. Commun. (2023). doi: 10.1038/s41467-023-36801-9 .

  • Category: Research Use Only (RUO)
  • Centralized service (CELLEX- VHIO and CDB- HCB, Barcelona)
  • TAT: between 10 and 12 working days since receiving the sample
  • Starting biological material: cfDNA from plasma or DNA from FFPE (block or slices)

Key features reported

SNVs& indels in 126 breast cancer-related genes
Incl.AKT1, BRAF, BRCA2, BRCA2, ESR1, ERBB2, PIK3CA, PTEN
Genome-widecopy number alterations
Incl.PTEN.
Scores for 150 signatures based on genome-wide CNA
5 subtypes classification with prognostic value
Tumor Fraction estimation in plasma
Xia,Y., et al. NatCommun (2019). doi:10.1038/s41467-019-13588-2
Prat,A., et al. NatCommun (2023). doi: 10.1038/s41467-023-36801-9
DNADX logo

DNADX®  is a groundbreaking test designed for patients facing advanced breast cancer.

Our proprietary software, used for diagnostic testing, examines the DNA from tumor tissue or circulating tumor DNA (ctDNA) in the blood.

By analyzing distinctive gene patterns, we uncover crucial details that go beyond single gene alterations, offering valuable insights to shape personalized and targeted treatment plans.

DNADX® is currently available in a Research Use Only (RUO) format and is in the process of being standardized, with plans to offer it for clinical use by 2027.

- Prat, et.al. Circulating tumor DNA reveals complex biological features with clinical relevance in metastatic breast cancer. Nature Communications | ( 2023) 14:1157- Xia, Youli, et. al. Genetic determinants of the molecular portraits of epithelial cancers. Nature Communications | (2019) 10:5666- Brasó-Maristany F et al. ctDNA-based DNADX in hormone receptor-positive and HER2-negative (HR+/HER2-)
advanced breast cancer following endocrine therapy and CDK4/6 inhibition: a correlative analysis from the randomized phase 2 PARSIFAL trial. SABCS 2023 (data on file). - Tarantino P et al. Impact of HER2 expression dynamics on the REaL-world actIvity of trastuzumab dEruxtecan for adVanced brEast cancer (RELIEVE). SABCS 2023 (data on file)